FI963150A0 - HIV-infektoitujen solujen kohdistettu sytolyysi kimeeristä CD4-reseptoria sisältävillä soluille - Google Patents
HIV-infektoitujen solujen kohdistettu sytolyysi kimeeristä CD4-reseptoria sisältävillä soluilleInfo
- Publication number
- FI963150A0 FI963150A0 FI963150A FI963150A FI963150A0 FI 963150 A0 FI963150 A0 FI 963150A0 FI 963150 A FI963150 A FI 963150A FI 963150 A FI963150 A FI 963150A FI 963150 A0 FI963150 A0 FI 963150A0
- Authority
- FI
- Finland
- Prior art keywords
- hiv
- receptor
- cells
- chimeric
- infected cell
- Prior art date
Links
- 108010041397 CD4 Antigens Proteins 0.000 title 1
- 206010057248 Cell death Diseases 0.000 title 1
- 230000009089 cytolysis Effects 0.000 title 1
- 108700010039 chimeric receptor Proteins 0.000 abstract 3
- 241000124008 Mammalia Species 0.000 abstract 2
- 230000001225 therapeutic effect Effects 0.000 abstract 2
- 208000031886 HIV Infections Diseases 0.000 abstract 1
- 208000037357 HIV infectious disease Diseases 0.000 abstract 1
- 230000024932 T cell mediated immunity Effects 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 abstract 1
- 230000003834 intracellular effect Effects 0.000 abstract 1
- 239000012528 membrane Substances 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 230000011664 signaling Effects 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/13—Tumour cells, irrespective of tissue of origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
- A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/464838—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70514—CD4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/023—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a poxvirus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Virology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Developmental Biology & Embryology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Reproductive Health (AREA)
- Wood Science & Technology (AREA)
- Mycology (AREA)
- General Engineering & Computer Science (AREA)
- Gynecology & Obstetrics (AREA)
- Hematology (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- AIDS & HIV (AREA)
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US19539594A | 1994-02-14 | 1994-02-14 | |
US19539594 | 1994-02-14 | ||
US28439194 | 1994-08-02 | ||
US08/284,391 US5851828A (en) | 1991-03-07 | 1994-08-02 | Targeted cytolysis of HIV-infected cells by chimeric CD4 receptor-bearing cells |
US9500454 | 1995-01-12 | ||
PCT/US1995/000454 WO1995021528A1 (en) | 1994-02-14 | 1995-01-12 | Targeted cytolysis of hiv-infected cells by chimeric cd4 receptor-bearing cells |
Publications (3)
Publication Number | Publication Date |
---|---|
FI963150A0 true FI963150A0 (fi) | 1996-08-12 |
FI963150A FI963150A (fi) | 1996-10-10 |
FI120264B FI120264B (fi) | 2009-08-31 |
Family
ID=26890956
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FI963150A FI120264B (fi) | 1994-02-14 | 1996-08-12 | Membraaniin sitoutunut kimeerinen respetoriproteiini |
Country Status (21)
Country | Link |
---|---|
US (3) | US5851828A (fi) |
EP (1) | EP0750457B1 (fi) |
JP (1) | JP3832850B2 (fi) |
KR (1) | KR100289253B1 (fi) |
CN (1) | CN1318576C (fi) |
AT (1) | ATE308888T1 (fi) |
AU (1) | AU690204B2 (fi) |
BR (1) | BR9506783A (fi) |
CA (1) | CA2182890C (fi) |
CZ (1) | CZ293969B6 (fi) |
DE (1) | DE69534589T2 (fi) |
DK (1) | DK0750457T3 (fi) |
ES (1) | ES2249766T3 (fi) |
FI (1) | FI120264B (fi) |
HU (1) | HU220100B (fi) |
IL (1) | IL112390A (fi) |
NO (1) | NO319378B1 (fi) |
NZ (1) | NZ279123A (fi) |
PL (1) | PL180066B1 (fi) |
UA (1) | UA42760C2 (fi) |
WO (1) | WO1995021528A1 (fi) |
Families Citing this family (97)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6319494B1 (en) | 1990-12-14 | 2001-11-20 | Cell Genesys, Inc. | Chimeric chains for receptor-associated signal transduction pathways |
US6407221B1 (en) | 1990-12-14 | 2002-06-18 | Cell Genesys, Inc. | Chimeric chains for receptor-associated signal transduction pathways |
US5851828A (en) | 1991-03-07 | 1998-12-22 | The General Hospital Corporation | Targeted cytolysis of HIV-infected cells by chimeric CD4 receptor-bearing cells |
US7049136B2 (en) | 1991-03-07 | 2006-05-23 | The General Hospital Corporation | Redirection of cellular immunity by receptor chimeras |
US5912170A (en) | 1991-03-07 | 1999-06-15 | The General Hospital Corporation | Redirection of cellular immunity by protein-tyrosine kinase chimeras |
US6004811A (en) | 1991-03-07 | 1999-12-21 | The Massachussetts General Hospital | Redirection of cellular immunity by protein tyrosine kinase chimeras |
US6753162B1 (en) | 1991-03-07 | 2004-06-22 | The General Hospital Corporation | Targeted cytolysis of HIV-infected cells by chimeric CD4 receptor-bearing cells |
PT804552E (pt) * | 1993-07-16 | 2003-08-29 | Gen Hospital Corp | Redireccionamento da imunidade cellar por quimeras de receptores |
ATE234011T1 (de) * | 1994-08-02 | 2003-03-15 | Gen Hospital Corp | Zellen, die einen cd4-scheinrezeptor tragen und entsprechende moleküle und verfahren |
GB9520641D0 (en) * | 1995-10-10 | 1995-12-13 | Medical Res Council | Improvements in or relating to protection against intracellular infection |
AUPN980796A0 (en) | 1996-05-13 | 1996-06-06 | Australian Membrane And Biotechnology Research Institute | Improved reservoir components |
US6544523B1 (en) | 1996-11-13 | 2003-04-08 | Chiron Corporation | Mutant forms of Fas ligand and uses thereof |
EP0893507A1 (en) * | 1997-07-25 | 1999-01-27 | Institut Gustave Roussy | Use of MHC class II ligands (CD4 and LAG-3) as adjuvant for vaccination and of LAG-3 in cancer treatment |
US6610043B1 (en) | 1999-08-23 | 2003-08-26 | Bistech, Inc. | Tissue volume reduction |
GB9925853D0 (en) * | 1999-11-01 | 1999-12-29 | Celltech Therapeutics Ltd | Biological products |
DE19957838C2 (de) * | 1999-11-25 | 2002-11-21 | Pette Heinrich Inst | Gentherapie von HIV-Infizierten durch Expression von Membran-verankerten gp41-Peptiden |
US7994298B2 (en) | 2004-09-24 | 2011-08-09 | Trustees Of Dartmouth College | Chimeric NK receptor and methods for treating cancer |
IN2014DN06624A (fi) | 2005-10-18 | 2015-07-10 | Univ Colorado | |
WO2007148470A1 (ja) * | 2006-06-22 | 2007-12-27 | River Bell Co. | 処理装置、処理方法及びプラズマ源 |
EA021131B1 (ru) | 2008-05-16 | 2015-04-30 | Тэйга Байотекнолоджис, Инк. | Антитела и способы их получения |
EP3916010A1 (en) | 2008-08-28 | 2021-12-01 | Taiga Biotechnologies, Inc. | Modulators of myc, methods of using the same and methods of identifying agents that modulate myc |
US9273283B2 (en) | 2009-10-29 | 2016-03-01 | The Trustees Of Dartmouth College | Method of producing T cell receptor-deficient T cells expressing a chimeric receptor |
US9181527B2 (en) | 2009-10-29 | 2015-11-10 | The Trustees Of Dartmouth College | T cell receptor-deficient T cell compositions |
US9833480B2 (en) | 2010-04-14 | 2017-12-05 | Prospect Chartercare, Llc | Methods and compositions for treating HIV |
US9833476B2 (en) | 2011-08-31 | 2017-12-05 | The Trustees Of Dartmouth College | NKP30 receptor targeted therapeutics |
CN110511278A (zh) | 2012-05-07 | 2019-11-29 | 达特茅斯大学理事会 | 抗b7-h6抗体、融合蛋白及其使用方法 |
JP6285930B2 (ja) | 2012-07-20 | 2018-02-28 | タイガ バイオテクノロジーズ,インク. | 造血コンパートメントの再構築及び自家再構築の増進 |
RU2019126655A (ru) | 2012-08-20 | 2019-11-12 | Фред Хатчинсон Кансэр Рисёч Сентер | Нуклеиновые кислоты, кодирующие химерные рецепторы, полипептидные химерные рецепторы, кодируемые ими, векторы экспрессии, содержащие их, выделенные клетки-хозяева, содержащие их, композиции, содержащие выделенные клетки-хозяева, а также способы получения выделенных клеток-хозяев in vitro, способы выбора нуклеиновых кислот, кодирующих химерные рецепторы, in vitro и способы проведения клеточной иммунотерапии у субъекта, имеющего опухоль |
US10272115B2 (en) | 2013-03-11 | 2019-04-30 | Taiga Biotechnologies, Inc. | Production and use of red blood cells |
WO2015077717A1 (en) | 2013-11-25 | 2015-05-28 | The Broad Institute Inc. | Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status |
WO2015085147A1 (en) | 2013-12-05 | 2015-06-11 | The Broad Institute Inc. | Polymorphic gene typing and somatic change detection using sequencing data |
KR20230076867A (ko) | 2013-12-20 | 2023-05-31 | 더 브로드 인스티튜트, 인코퍼레이티드 | 신생항원 백신과의 병용 요법 |
WO2016100975A1 (en) | 2014-12-19 | 2016-06-23 | Massachsetts Institute Ot Technology | Molecular biomarkers for cancer immunotherapy |
EP3757211A1 (en) | 2014-12-19 | 2020-12-30 | The Broad Institute, Inc. | Methods for profiling the t-cell-receptor repertoire |
WO2016138491A1 (en) * | 2015-02-27 | 2016-09-01 | Icell Gene Therapeutics Llc | Chimeric antigen receptors (cars) targeting hematologic malignancies, compositions and methods of use thereof |
PE20180670A1 (es) | 2015-05-20 | 2018-04-19 | Broad Inst Inc | Neoantigenos compartidos |
AU2016279062A1 (en) | 2015-06-18 | 2019-03-28 | Omar O. Abudayyeh | Novel CRISPR enzymes and systems |
CA2999496A1 (en) * | 2015-09-22 | 2017-03-30 | The Trustees Of The University Of Pennsylvania | Method of redirecting t cells to treat hiv infection |
WO2017069958A2 (en) | 2015-10-09 | 2017-04-27 | The Brigham And Women's Hospital, Inc. | Modulation of novel immune checkpoint targets |
WO2017075465A1 (en) | 2015-10-28 | 2017-05-04 | The Broad Institute Inc. | Compositions and methods for evaluating and modulating immune responses by detecting and targeting gata3 |
WO2017075451A1 (en) | 2015-10-28 | 2017-05-04 | The Broad Institute Inc. | Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1 |
WO2017075478A2 (en) | 2015-10-28 | 2017-05-04 | The Broad Institute Inc. | Compositions and methods for evaluating and modulating immune responses by use of immune cell gene signatures |
AU2016355178B9 (en) | 2015-11-19 | 2019-05-30 | Massachusetts Institute Of Technology | Lymphocyte antigen CD5-like (CD5L)-interleukin 12B (p40) heterodimers in immunity |
WO2017184590A1 (en) | 2016-04-18 | 2017-10-26 | The Broad Institute Inc. | Improved hla epitope prediction |
CN106267409B (zh) * | 2016-07-01 | 2019-02-01 | 翁炳焕 | 艾滋病生物治疗反应器 |
CN106178163B (zh) * | 2016-07-01 | 2019-02-01 | 翁炳焕 | 艾滋病生物细胞免疫治疗仪 |
WO2018035364A1 (en) | 2016-08-17 | 2018-02-22 | The Broad Institute Inc. | Product and methods useful for modulating and evaluating immune responses |
US20190262399A1 (en) | 2016-09-07 | 2019-08-29 | The Broad Institute, Inc. | Compositions and methods for evaluating and modulating immune responses |
WO2018067991A1 (en) | 2016-10-07 | 2018-04-12 | The Brigham And Women's Hospital, Inc. | Modulation of novel immune checkpoint targets |
JP6799683B2 (ja) | 2016-12-02 | 2020-12-16 | タイガ バイオテクノロジーズ,インク. | ナノ粒子製剤 |
WO2018140391A1 (en) | 2017-01-24 | 2018-08-02 | The Broad Institute, Inc. | Compositions and methods for detecting a mutant variant of a polynucleotide |
WO2018148224A1 (en) | 2017-02-07 | 2018-08-16 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Phospholipid ether (ple) car t cell tumor targeting (ctct) agents |
DK3580561T3 (da) | 2017-02-12 | 2023-12-18 | Biontech Us Inc | Hla-baserede metoder, sammensætninger og anvendelse heraf |
US11850262B2 (en) | 2017-02-28 | 2023-12-26 | Purdue Research Foundation | Compositions and methods for CAR T cell therapy |
US11963966B2 (en) | 2017-03-31 | 2024-04-23 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for treating ovarian tumors |
WO2018183921A1 (en) | 2017-04-01 | 2018-10-04 | The Broad Institute, Inc. | Methods and compositions for detecting and modulating an immunotherapy resistance gene signature in cancer |
EP3610266A4 (en) | 2017-04-12 | 2021-04-21 | Massachusetts Eye and Ear Infirmary | TUMOR SIGNATURE OF METASTASIS, COMPOSITIONS OF SUBSTANCES AND USES THEREOF |
CA3059643A1 (en) | 2017-04-13 | 2018-10-18 | Cellectis | New sequence specific reagents targeting ccr5 in primary hematopoietic cells |
WO2018195019A1 (en) | 2017-04-18 | 2018-10-25 | The Broad Institute Inc. | Compositions for detecting secretion and methods of use |
KR20240059648A (ko) | 2017-04-19 | 2024-05-07 | 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 | 조작된 항원 수용체를 발현하는 면역 세포 |
CN107014658B (zh) * | 2017-05-27 | 2023-08-25 | 四川省肿瘤医院 | 提取游离细胞的方法及试剂盒 |
US11897953B2 (en) | 2017-06-14 | 2024-02-13 | The Broad Institute, Inc. | Compositions and methods targeting complement component 3 for inhibiting tumor growth |
WO2019027465A1 (en) | 2017-08-03 | 2019-02-07 | Taiga Biotechnologies, Inc. | PHARMACEUTICAL METHODS AND COMPOSITIONS FOR THE TREATMENT OF MELANOMA |
US10149898B2 (en) | 2017-08-03 | 2018-12-11 | Taiga Biotechnologies, Inc. | Methods and compositions for the treatment of melanoma |
US11618896B2 (en) | 2017-09-21 | 2023-04-04 | The Broad Institute, Inc. | Systems, methods, and compositions for targeted nucleic acid editing |
WO2019084055A1 (en) | 2017-10-23 | 2019-05-02 | Massachusetts Institute Of Technology | CLASSIFICATION OF GENETIC VARIATION FROM UNICELLULAR TRANSCRIPTOMS |
WO2019094983A1 (en) | 2017-11-13 | 2019-05-16 | The Broad Institute, Inc. | Methods and compositions for treating cancer by targeting the clec2d-klrb1 pathway |
US11994512B2 (en) | 2018-01-04 | 2024-05-28 | Massachusetts Institute Of Technology | Single-cell genomic methods to generate ex vivo cell systems that recapitulate in vivo biology with improved fidelity |
US20200368280A1 (en) * | 2018-01-12 | 2020-11-26 | Viracta Therapeutics, Inc. | Epigenetic modifiers for use in cellular immunotherapy |
CN112292138A (zh) | 2018-01-22 | 2021-01-29 | 西雅图儿童医院(Dba西雅图儿童研究所) | Car t细胞的使用方法 |
US11957695B2 (en) | 2018-04-26 | 2024-04-16 | The Broad Institute, Inc. | Methods and compositions targeting glucocorticoid signaling for modulating immune responses |
US20210371932A1 (en) | 2018-06-01 | 2021-12-02 | Massachusetts Institute Of Technology | Methods and compositions for detecting and modulating microenvironment gene signatures from the csf of metastasis patients |
WO2019241273A1 (en) | 2018-06-11 | 2019-12-19 | The Broad Institute, Inc. | Lineage tracing using mitochondrial genome mutations and single cell genomics |
WO2020041384A1 (en) | 2018-08-20 | 2020-02-27 | The Broad Institute, Inc. | 3-phenyl-2-cyano-azetidine derivatives, inhibitors of rna-guided nuclease activity |
US20210177832A1 (en) | 2018-08-20 | 2021-06-17 | The Broad Institute, Inc. | Inhibitors of rna-guided nuclease target binding and uses thereof |
WO2020041387A1 (en) | 2018-08-20 | 2020-02-27 | The Brigham And Women's Hospital, Inc. | Degradation domain modifications for spatio-temporal control of rna-guided nucleases |
WO2020072700A1 (en) | 2018-10-02 | 2020-04-09 | Dana-Farber Cancer Institute, Inc. | Hla single allele lines |
US20210379057A1 (en) | 2018-10-16 | 2021-12-09 | Massachusetts Institute Of Technology | Nutlin-3a for use in treating a mycobacterium tuberculosis infection |
US20220170097A1 (en) | 2018-10-29 | 2022-06-02 | The Broad Institute, Inc. | Car t cell transcriptional atlas |
US20210388389A1 (en) | 2018-10-30 | 2021-12-16 | Yale University | Compositions and methods for rapid and modular generation of chimeric antigen receptor t cells |
US20220062394A1 (en) | 2018-12-17 | 2022-03-03 | The Broad Institute, Inc. | Methods for identifying neoantigens |
AU2019404547A1 (en) | 2018-12-21 | 2021-07-22 | Biontech Us Inc. | Method and systems for prediction of HLA class II-specific epitopes and characterization of CD4+ T cells |
US11739156B2 (en) | 2019-01-06 | 2023-08-29 | The Broad Institute, Inc. Massachusetts Institute of Technology | Methods and compositions for overcoming immunosuppression |
WO2020186101A1 (en) | 2019-03-12 | 2020-09-17 | The Broad Institute, Inc. | Detection means, compositions and methods for modulating synovial sarcoma cells |
EP3942023A1 (en) | 2019-03-18 | 2022-01-26 | The Broad Institute, Inc. | Compositions and methods for modulating metabolic regulators of t cell pathogenicity |
WO2020236967A1 (en) | 2019-05-20 | 2020-11-26 | The Broad Institute, Inc. | Random crispr-cas deletion mutant |
WO2020243371A1 (en) | 2019-05-28 | 2020-12-03 | Massachusetts Institute Of Technology | Methods and compositions for modulating immune responses |
WO2021030627A1 (en) | 2019-08-13 | 2021-02-18 | The General Hospital Corporation | Methods for predicting outcomes of checkpoint inhibition and treatment thereof |
US20220298501A1 (en) | 2019-08-30 | 2022-09-22 | The Broad Institute, Inc. | Crispr-associated mu transposase systems |
US11981922B2 (en) | 2019-10-03 | 2024-05-14 | Dana-Farber Cancer Institute, Inc. | Methods and compositions for the modulation of cell interactions and signaling in the tumor microenvironment |
US11793787B2 (en) | 2019-10-07 | 2023-10-24 | The Broad Institute, Inc. | Methods and compositions for enhancing anti-tumor immunity by targeting steroidogenesis |
US11844800B2 (en) | 2019-10-30 | 2023-12-19 | Massachusetts Institute Of Technology | Methods and compositions for predicting and preventing relapse of acute lymphoblastic leukemia |
EP4196579A1 (en) | 2020-08-13 | 2023-06-21 | Yale University | Compositions and methods for engineering and selection of car t cells with desired phenotypes |
WO2023173137A1 (en) | 2022-03-11 | 2023-09-14 | Yale University | Compositions and methods for efficient and stable genetic modification of eukaryotic cells |
WO2023220644A1 (en) | 2022-05-10 | 2023-11-16 | Yale University | Compositions and methods of synthetic ctla-4 tails for reprogramming of car-t cells and enhancement of anti-tumor efficacy |
WO2024077256A1 (en) | 2022-10-07 | 2024-04-11 | The General Hospital Corporation | Methods and compositions for high-throughput discovery ofpeptide-mhc targeting binding proteins |
WO2024124044A1 (en) | 2022-12-07 | 2024-06-13 | The Brigham And Women’S Hospital, Inc. | Compositions and methods targeting sat1 for enhancing anti¬ tumor immunity during tumor progression |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL108169C (fi) | 1957-01-30 | |||
US4873190A (en) * | 1984-06-13 | 1989-10-10 | Massachusetts Institute Of Technology | Heterodimeric T lymphocyte receptor |
GB8422238D0 (en) * | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
US4690915A (en) * | 1985-08-08 | 1987-09-01 | The United States Of America As Represented By The Department Of Health And Human Services | Adoptive immunotherapy as a treatment modality in humans |
US5030576A (en) * | 1986-04-30 | 1991-07-09 | Genentech, Inc. | Receptors for efficient determination of ligands and their antagonists or agonists |
US4946778A (en) * | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
ATE87659T1 (de) * | 1986-09-02 | 1993-04-15 | Enzon Lab Inc | Bindungsmolekuele mit einzelpolypeptidkette. |
US4808151A (en) * | 1987-04-27 | 1989-02-28 | E. I. Du Pont De Nemours And Company | Simplified method for the preparation of human lymphokine activated killer cells |
US5091513A (en) * | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
JPS6463394A (en) * | 1987-09-04 | 1989-03-09 | Kyowa Hakko Kogyo Kk | Novel chimera polypeptide |
US5336603A (en) * | 1987-10-02 | 1994-08-09 | Genentech, Inc. | CD4 adheson variants |
PT88641B (pt) * | 1987-10-02 | 1993-04-30 | Genentech Inc | Metodo para a preparacao de uma variante de adesao |
PT89484B (pt) * | 1988-01-22 | 1994-03-31 | Gen Hospital Corp | Genes clonados codificadores de proteinas de fusao ig-cd4 e sua utilizacao |
IL86278A (en) * | 1988-05-04 | 2003-06-24 | Yeda Res & Dev | Endowing cells with antibody specificity using chimeric t cell receptor |
CA2000878C (en) * | 1988-10-18 | 1999-06-29 | Jean-Pierre Kinet | Cdnas coding for the subunit of the high-affinity receptor for immunoglobulin e |
US5225538A (en) * | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
FR2644463A1 (fi) * | 1989-03-17 | 1990-09-21 | Pasteur Institut | |
EP0394827A1 (en) * | 1989-04-26 | 1990-10-31 | F. Hoffmann-La Roche Ag | Chimaeric CD4-immunoglobulin polypeptides |
WO1991010736A2 (en) * | 1990-01-19 | 1991-07-25 | Dana Farber Cancer Institute | CLONING AND CHARACTERIZATION OF THE CD3θ SUBUNIT |
EP0517895B1 (en) * | 1990-12-14 | 1996-11-20 | Cell Genesys, Inc. | Chimeric chains for receptor-associated signal transduction pathways |
US6004811A (en) * | 1991-03-07 | 1999-12-21 | The Massachussetts General Hospital | Redirection of cellular immunity by protein tyrosine kinase chimeras |
US5851828A (en) | 1991-03-07 | 1998-12-22 | The General Hospital Corporation | Targeted cytolysis of HIV-infected cells by chimeric CD4 receptor-bearing cells |
NZ241855A (en) * | 1991-03-07 | 1994-04-27 | Gen Hospital Corp | Use of therapeutic cells to obtain cellular response to infection, tumours or autoimmune-generated cells, cells with chimaeric receptors (with binding component and destruction signal), dna encoding the receptor, vectors and antibodies to receptor |
US6753162B1 (en) * | 1991-03-07 | 2004-06-22 | The General Hospital Corporation | Targeted cytolysis of HIV-infected cells by chimeric CD4 receptor-bearing cells |
US5912170A (en) | 1991-03-07 | 1999-06-15 | The General Hospital Corporation | Redirection of cellular immunity by protein-tyrosine kinase chimeras |
US5843728A (en) * | 1991-03-07 | 1998-12-01 | The General Hospital Corporation | Redirection of cellular immunity by receptor chimeras |
WO1993019163A1 (en) * | 1992-03-18 | 1993-09-30 | Yeda Research And Development Co, Ltd. | Chimeric receptor genes and cells transformed therewith |
PT804552E (pt) | 1993-07-16 | 2003-08-29 | Gen Hospital Corp | Redireccionamento da imunidade cellar por quimeras de receptores |
US5439819A (en) * | 1993-08-27 | 1995-08-08 | The Regents Of The University Of California | Chimeric protein tyrosine kinases |
US5712149A (en) | 1995-02-03 | 1998-01-27 | Cell Genesys, Inc. | Chimeric receptor molecules for delivery of co-stimulatory signals |
JP3782521B2 (ja) | 1996-08-23 | 2006-06-07 | 富士通コンポーネント株式会社 | 押釦構造およびキーボード |
-
1994
- 1994-08-02 US US08/284,391 patent/US5851828A/en not_active Expired - Lifetime
-
1995
- 1995-01-12 NZ NZ279123A patent/NZ279123A/en not_active IP Right Cessation
- 1995-01-12 JP JP52121395A patent/JP3832850B2/ja not_active Expired - Lifetime
- 1995-01-12 DE DE69534589T patent/DE69534589T2/de not_active Expired - Lifetime
- 1995-01-12 WO PCT/US1995/000454 patent/WO1995021528A1/en active IP Right Grant
- 1995-01-12 AT AT95907414T patent/ATE308888T1/de active
- 1995-01-12 ES ES95907414T patent/ES2249766T3/es not_active Expired - Lifetime
- 1995-01-12 DK DK95907414T patent/DK0750457T3/da active
- 1995-01-12 CZ CZ19962331A patent/CZ293969B6/cs not_active IP Right Cessation
- 1995-01-12 AU AU15653/95A patent/AU690204B2/en not_active Expired
- 1995-01-12 BR BR9506783A patent/BR9506783A/pt not_active Application Discontinuation
- 1995-01-12 HU HU9602182A patent/HU220100B/hu unknown
- 1995-01-12 PL PL95315908A patent/PL180066B1/pl unknown
- 1995-01-12 KR KR1019960704450A patent/KR100289253B1/ko not_active IP Right Cessation
- 1995-01-12 CN CNB951925598A patent/CN1318576C/zh not_active Expired - Lifetime
- 1995-01-12 EP EP95907414A patent/EP0750457B1/en not_active Expired - Lifetime
- 1995-01-12 UA UA96093460A patent/UA42760C2/uk unknown
- 1995-01-12 CA CA002182890A patent/CA2182890C/en not_active Expired - Lifetime
- 1995-01-19 IL IL112390A patent/IL112390A/en not_active IP Right Cessation
-
1996
- 1996-08-12 FI FI963150A patent/FI120264B/fi not_active IP Right Cessation
- 1996-08-13 NO NO19963379A patent/NO319378B1/no not_active IP Right Cessation
-
1998
- 1998-12-22 US US09/218,950 patent/US6284240B1/en not_active Expired - Lifetime
-
2001
- 2001-08-24 US US09/939,537 patent/US7094599B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FI963150A0 (fi) | HIV-infektoitujen solujen kohdistettu sytolyysi kimeeristä CD4-reseptoria sisältävillä soluille | |
DK0871495T3 (da) | Omdirigering af cellulær immunitet med receptorkimærer | |
UA41870C2 (uk) | Спосіб направлення клітинної відповіді на інфекційний агент, клітину, інфіковану вказаним агентом, пухлинну, злоякісну клітину або аутоімунну клітину (варіанти), клітина, яка експресує мембранозв'язаний білковий химерний рецептор (варіанти), днк,що кодує химерний рецептор, вектор, спосіб лікування інфекції вірусу імунодефіциту(варіанти) | |
WO2002077029A3 (en) | Cd19-specific redirected immune cells | |
ZA961476B (en) | Redirection of cellular immunity by protein-tyrosine kinase chimeras | |
IL114778A0 (en) | Chimeric CD4 receptor-bearing cells membrane-bound receptors and DNA encoding the same | |
FI960178A0 (fi) | Soluvälitteisen immuniteetin uudelleensuuntaaminen reseptorikimeerojen avulla | |
NZ330034A (en) | Method of treating HIV in mammals by administering cells bearing CD4 decoy receptors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Patent granted |
Ref document number: 120264 Country of ref document: FI |
|
MA | Patent expired |